Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr;25(3):411-422.
doi: 10.1007/s10198-023-01593-8. Epub 2023 May 22.

A cost-of-illness study of Behçet syndrome in Italy

Affiliations
Review

A cost-of-illness study of Behçet syndrome in Italy

Valentina Lorenzoni et al. Eur J Health Econ. 2024 Apr.

Abstract

Objective: This study aims at evaluating the cost-of-illness (COI) of patients diagnosed with Behcet's syndrome (BS) in Italy, trying to depict the impact of different costs' components to the overall economic burden and analysing the variability of costs according to years since diagnosis and age at first symptoms.

Methods: With a cross-sectional evaluation, we surveyed a large sample of BS patients in Italy assessing several dimensions related to BS, also including fact related to the use of health resources utilization, formal and informal care, and productivity losses. Overall costs, direct health, direct non-health, and indirect costs were thus estimated per patient/year considering a Societal perspective and the impact of years since diagnosis, age at first symptoms on costs was evaluated using generalized linear model (GLM) and a two-part model, adjusting for age and distinguishing among employed and non-employed responders.

Results: A total of 207 patients were considered in the present study. From the perspective of the Society, mean overall costs for BS patient were estimated to be 21,624 € (0;193,617) per patient/year. Direct non-health expenses were the main costs component accounting for 58% of the overall costs, followed direct health costs, 36%, while indirect costs because of productivity losses represented 6% of the overall costs. Being employed resulted in significantly lower overall costs (p = 0.006). Results from the multivariate regression analyses suggested that the probability of incurring in overall costs equal to zero decreased as time from BS diagnosis is 1 year or more as compared to newly diagnosed patients (p < 0.001); while among those incurring in expenses, costs decreased for those experiencing first symptoms between 21 and 30 years (p = 0.027) or later (p = 0.032) as compared to those having symptoms earlier. Similar findings emerged among the subgroups of patients declaring themselves as workers, while no impact of years since diagnosis or age of first symptoms was found among non-workers.

Conclusions: The present study offers a comprehensive overview of the economic consequences imposed by BS in a societal perspective, providing insights into the distribution of the different costs component related to BS, thus helping the development of targeted policies.

Keywords: Behçet; Cost-of-illness; Economic.

PubMed Disclaimer

Conflict of interest statement

All the authors declared they have no conflict of interest to declare.

Figures

Fig. 1
Fig. 1
Contribution of the different cost’ components to the total cost

References

    1. Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, Murphy D, Le Cam Y, Rath A. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur. J. Hum. Genet. 2020;28:165–173. doi: 10.1038/S41431-019-0508-0. - DOI - PMC - PubMed
    1. García-Pérez L, Linertová R, Valcárcel-Nazco C, Posada M, Gorostiza I, Serrano-Aguilar P. Cost-of-illness studies in rare diseases: a scoping review. Orphanet J. Rare Dis. 2021 doi: 10.1186/S13023-021-01815-3. - DOI - PMC - PubMed
    1. Posarelli C, Maglionico MN, Talarico R, Covello G, Figus M. Behçet’s syndrome and ocular involvement: changes over time. Clin. Exp. Rheumatol. 2020;38:86–93. - PubMed
    1. Hatemi G, Seyahi E, Fresko I, Talarico R, Uçar D, Hamuryudan V. One year in review 2021: Behçet’s syndrome. Clin. Exp. Rheumatol. 2021;39(Suppl 132):S3–S13. doi: 10.55563/CLINEXPRHEUMATOL/LNVC9K. - DOI - PubMed
    1. Yazici Y. Management of Behçet syndrome. Curr. Opin. Rheumatol. 2020;32:35–40. doi: 10.1097/BOR.0000000000000666. - DOI - PubMed